MiNK Therapeutics, Inc. (INKT) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.
The consensus price target is $35.00, representing an upside of 159.1% from the current price $13.51.
Analysts estimate Earnings Per Share (EPS) of $-3.65 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-285.82 vs est $-3.65 (missed -7738.2%). 2025: actual $-2.93 vs est $-3.07 (beat +4.6%). Analyst accuracy: 48%.
INKT Stock — 12-Month Price Forecast
$35.00
▲ +159.07% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for MiNK Therapeutics, Inc., the price target is $35.00.
The average price target represents a +159.07% change from the last price of $13.51.
INKT Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to MiNK Therapeutics, Inc. in the past 3 months
EPS Estimates — INKT
48%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$285.82
vs Est –$3.65
▼ 98.7% off
2025
Actual –$2.93
vs Est –$3.07
▲ 4.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — INKT
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
